Stocks rally despite hot CPI data 🔥

A hotter-than-expected inflation read on February's CPI report didn't stop the market from rallying on Tuesday.

Sponsored by

Good Afternoon! 

Hey, everyone. It's Adam from Elite Trade Club. 

Here’s what moved the market today.

Markets 📈

Stocks rallied on Tuesday despite an expected uptick in inflation last month. The Nasdaq led, followed by the S&P 500 and Dow.

  • DJIA [+0.6%]

  • S&P 500 [+1.1%]

  • Nasdaq [+1.5%]

  • Russell 2K [<0.1%]

How did @TheArbFather make $10,000+ profit in February?

His secret sauce: Arbitrage betting.

Instead of getting bettings tips from slick-talking handicappers, TheArbFather bets on both sides of an outcome to guarantee a risk-free return. An example of this is betting on a game total to be over 224.5 AND under 224.5.

This might sound too good to be true, but the reason this can happen is sportsbooks set their lines for games independently. Sometimes, they make mistakes and there are situations where FanDuel’s odds are different from DraftKings’ odds.

Unless you are a PhD-wielding, Python-coding, Excel-Wizard… finding arbitrage opportunities consistently has been out of reach. Until now…

OddsJam scans millions of odds every second and finds these need-in-a-haystack opportunities that you can bet on to secure a risk-free profit.

» Want an Ad-Free Experience + Top Growth Stock Picks? Upgrade Now! 

Market-Moving News 🔎 

 📈 Inflation Ticks Up: Navigating Fed's Next Moves

The latest Consumer Price Index (CPI) report has revealed a subtle uptick in U.S. inflation for February, clocking in at a 3.2% increase from the previous year. This figure slightly surpasses the 3.1% increase economists had forecasted, signaling a continued, albeit gentle, pressure on the economic landscape.

This increment marks the second consecutive month where inflation has outstripped expectations, hinting at the persistent inflationary trends that have become a focal point for market watchers and policymakers alike.

🏦 Delicate Balance 
The February CPI report arrives at a critical juncture for the Federal Reserve, presenting a complex backdrop as it gears up for its next meeting. While the slight rise in inflation does little to sway the broader expectation that the Fed will initiate rate cuts later this year, it underscores the importance of a cautious approach.

The central bank's current wait-and-see attitude towards adjusting rates reflects a strategic deliberation aimed at striking the right balance between fostering economic growth and curbing inflation.

⏳ Timing Over Trajectory 
Amidst the backdrop of gradually subsiding inflation from its 40-year peak, the conversation within the Fed has shifted towards the timing of rate reductions rather than contemplating further hikes.

This nuanced stance, informed by the most aggressive rate increases in decades, emphasizes the Fed's commitment to recalibrating its monetary policy in alignment with evolving economic indicators.

📊 Market Perspectives 
Eric Rosengren, former head of the Boston Fed, views the latest inflation data as consistent with the expectations set during the Fed's December meeting, which anticipated three rate cuts within the year.

The investment community, aligning with this outlook, is setting its sights on June for the potential initiation of rate reductions. This collective anticipation underscores a shared belief in the necessity of adaptive monetary strategies to navigate the current economic environment effectively.

Top Winners and Losers 🔥

HNR Acquisition [HNRA] $4.47 (+121.2%)
said it has discovered up to 34 million barrels of additional untapped oil reserves in its Grayburg-Jackson oil field.

Regulus Therapeutic [RGLS] $2.36 (+71.0%)
published promising new clinical data from a Phase 1b trial of RGLS8429 for autosomal dominant polycystic kidney disease.

ClearOne [CLRO] $2.06 (+127.5%)
announced a special dividend of $0.50 per share.

Lexaria Bioscience [LEXX] $4.18 (33.1%)
pulled back after advancing for several days in a row following its announcement relating to its GLP-1 human pilot study last week.

Psyence Biomed [PBM] $1.23 (30.5%)
retreated after publishing a shareholder letter recapping recent progress and plans for future milestones on Monday.

Caribou Biosciences [CRBU] $5.02 (30.4%)
posted weaker-than-expected earnings and sales on its Q4 financial report published Monday evening.

That's it for today! Please, write us back, and let us know what you think of the Closing Bell Roundup. We're always eager to hear feedback from our members!

Thanks for reading. I'll see you at the next open! 

Best Regards,
Adam G.
Elite Trade Club

Text ELITESTOCKS to 47121 or click here to get our alerts on your mobile device, and never miss another fast-moving stock!

P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.